Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Due to the biological heterogeneity, 60%–70% of patients with major depressive disorder (MDD) do not respond to or achieve remission from first‐line antidepressants. Predicting neuroimaging biomarkers for early antidepressant treatment could guide initial antidepressant therapy.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Purpose</h3><p>To assess for neuroimaging biomarkers for antidepressant selection in early antidepressant treatment.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Study Type</h3><p>Prospective.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Subjects</h3><p>A total of 85 MDD patients from the major site and 33 MDD patients from an out‐of‐sample test site.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Field Strength/Sequence</h3><p>A 3.0 T, T1‐weighted imaging using a magnetization‐prepared rapid acquisition gradient‐echo sequence and diffusion tensor imaging (DTI) using an echo‐planar sequence.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Assessment</h3><p>Baseline DTI data of patients who achieved early improvement after 2‐weeks of antidepressant treatment (selective serotonin reuptake inhibitors [SSRI] or serotonin‐norepinephrine reuptake inhibitors [SNRI]) were analyzed. An ensemble model was constructed using data from the major site and then applied to assess the early response of patients at the out‐of‐sample test site.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Statistical Tests</h3><p>Support vector machine combined with leave‐one‐out cross‐validation were applied to construct the whole model from individual base models from different brain regions. Discriminative biomarkers were evaluated by calculating the changes in sensitivity and specificity obtained when removing a single base model from the whole model, the base model being removed changing in each run.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Training performance over MDD patients at the major site achieved 75% accuracy while performance with accuracy of 70% was achieved in the out‐of‐sample test site. Assessing sensitivity and specificity changes following the removal of single base models from the prominent model highlighted the functions of two neural circuitries: SSRI‐related emotion regulation circuitry, centered on the hippocampus (sensitivity changes: 10%) and amygdala (sensitivity changes: 11%); and SNRI‐related emotion and reward circuitry, centered on the putamen (specificity changes: 8%) and orbital part of superior frontal gyrus (specificity changes: 12%).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Data Conclusion</h3><p>These findings support future research on clinical antidepressant selection for MDD.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Evidence Level</h3><p>1</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Technical Efficacy</h3><p>Stage 2</p></section>

Shared and unique imaging-derived endo-phenotypes of two typical antidepressant-applicative depressive patients

Biotypes of major depressive disorder: Neuroimaging evidence from resting-state default mode network patterns.

Shared Differential Factors Underlying Individual Spontaneous Neural Activity Abnormalities in Major Depressive Disorder.

Dimensional subtyping of first-episode drug-naïve major depressive disorder: A multisite resting-state fMRI study

Identifying Subgroups of Major Depressive Disorder Using Brain Structural Covariance Networks and Mapping of Associated Clinical and Cognitive Variables

An Investigation into the Association Between Dopamine Receptor D1 Multilocus Genetic Variation, Multiparametric Magnetic Resonance Imaging, and Antidepressant Treatment

A Joint Study of Whole Exome Sequencing and Structural MRI Analysis in Major Depressive Disorder.

Distinct MRI-based functional and structural connectivity for antidepressant response prediction in major depressive disorder

Sub-hubs of Baseline Functional Brain Networks Are Related to Early Improvement Following Two-Week Pharmacological Therapy for Major Depressive Disorder.

Connectome Analysis of Functional and Structural Hemispheric Brain Networks in Major Depressive Disorder

Shared and disease-sensitive dysfunction across bipolar and unipolar disorder during depressive episodes: a transdiagnostic study

Molecular, Functional, and Structural Imaging of Major Depressive Disorder

Contrastive functional connectivity defines neurophysiology-informed symptom dimensions in major depression

Probing the Clinical and Brain Structural Boundaries of Bipolar and Major Depressive Disorder

Neuroanatomical dimensions in medication-free individuals with major depressive disorder and treatment response to SSRI antidepressant medications or placebo

Individualized Functional Connectome Identified Replicable Biomarkers for Dysphoric Symptoms in First-Episode Medication-Naïve Patients with Major Depressive Disorder

Optimizing Antidepressant Efficacy: Generalizable Multimodal Neuroimaging Biomarkers for Prediction of Treatment Response

Innovative Neuroimaging Biomarker Distinction of Major Depressive Disorder and Bipolar Disorder through Structural Connectome Analysis and Machine Learning Models

Predicting Neuroimaging Biomarkers for Antidepressant Selection in Early Treatment of Depression

Diagnosis of Major Depressive Disorder Based on Individualized Brain Functional and Structural Connectivity

Structural Neuroimaging and Molecular Signatures of Drug‐Naive Depression With Melancholic Features